Pursuant to the authorization granted by the annual general meeting on 14 November 2019, the board of directors of Ascelia Pharma AB (”Ascelia”) has resolved to issue and immediately thereafter repurchase  510,545 series C shares. The shares are issued and repurchased in accordance with the share saving program LTI 2019, which was adopted by the an ...

Our values inspire our ambitions, decision making and collaboration to help us reach our highest potential. INTEGRITY We build powerful relationship with mutual respect and adhere to the high ethical […]